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a b s t r a c t
Background: Tumour necrosis factor alpha (TNF) is a pro-inﬂammatory cytokine implicated in
atherosclerotic plaque formation. We investigated whether circulating TNF is prospectively associated
with myocardial infarction (MI) or stroke in the older general population, independently of established
cardiovascular risk factors and other inﬂammatory markers related to CHD risk.
Methods: We measured baseline TNF concentrations in stored serum samples of 362 incident MI and
299 incident stroke cases and controls (2 per case, frequency matched by age, gender and town) who
were ‘nested’ in parallel prospective studies of 4252 men and 4286 women aged 60–79 years assessed in
general practices in 24 British towns in 1998–2000 and followed up for an average 7 years for fatal and
non-fatal MI and stroke.
Results: TNF levels were 11.4% (95% CI 9.5, 13.3%) higher among MI cases than controls; geometric mean
1.84pg/mL compared to 1.63pg/mL, p (difference) <0.001. Participants in the top third of baseline TNFNF
rospective
ohort
levels had an age-adjusted odds ratio (OR) for MI of 1.75 (95%CI 1.22, 2.49) compared with those in the
bottom third, whichwas reduced to 1.47 (95%CI 1.01, 2.14) after adjustment for established cardiovascular
risk factors. However, further adjustment for C-reactive protein and interleukin-6 abolished the associ-
ation OR 1.33 (95% CI 0.91, 1.66) and the linear trend. Excluding subjects with pre-existing CVD did not
materially affect results. No signiﬁcant association between TNF and stroke was observed.
ugges
roke.Conclusions: This study s
associated with risk of st
. Introduction
Inﬂammation is important in the development and rupture
f atherosclerotic lesions leading to cardiovascular disease (CVD)
vents [1]. Population-based prospective studies report associa-
ions between circulating acute phase inﬂammatory markers and
HD (coronary heart disease) [2,3] and stroke [4]. Evidence is accu-
ulating that pro-inﬂammatory cytokines (e.g. interleukin 6 [IL-6])
Abbreviations: TNF, tumour necrosis factor alpha; MI, myocardial infarction;
VD, cardiovascular disease; CHD, coronary heart disease; OR, odds ratio; IQR, inter-
uartile range; CI, conﬁdence interval; CRP, C-reactive protein; IL-6, interleukin-6;
MI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure;
-PA, tissue plasminogen activator; LR, likelihood ratio.
∗ Corresponding author at: BritishRegionalHeart Study,UCLDepartment Primary
are & Population Health, Royal Free & University College Medical School, Rowland
ill Street, London NW3 2PF, UK. Tel.: +44 207 830 2230; fax: +44 20 7794 1224.
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Open access under CC BY-NC-ND license.ts that TNF is not a strong independent risk marker for MI, and is not
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are related to CHD risk [5]. Tumour necrosis factor alpha (TNF)
is a pro-inﬂammatory cytokine important in initiating inﬂamma-
tory responses [6]. Human studies and animal models implicate
TNF in atherosclerotic plaque formation [7,8]. TNF is producedby
macrophages, foam cells and mast cells (among others), promotes
cellular inﬁltrationof theplaque and stimulates productionof other
cytokines which increase plaque instability leading to thrombus
formation [9].
Higher circulating levels of TNFmight be expected to be asso-
ciated with increased CHD and stroke risks based on experimental
evidence, but epidemiologic evidence is inconsistent. Some [10–12]
but not all [13] cross-sectional data indicate positive associations
between TNF and degree of atherosclerosis or level of preva-
Open access under CC BY-NC-ND license.lent CVD, and some studies of secondary CHD report null ﬁndings
[13,14]. There are few prospective studies of healthy individu-
als [11,12], and they include fewer than 300 cases of hard CHD
endpoints [11–13,15]. Some studies report positive associations
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f TNF and stroke exist, the largest (n=591 cases of recurrent
troke) reported positive associations between TNF and stroke
16], althoughﬁndings forprimary stroke riskhavebeennull [11,17].
onsiderable uncertainty remains about the strength of association
f TNFwith risk of MI and stroke in generally healthy population
ohorts.
We investigate associations between serum TNF and risk of
I and stroke in two large parallel prospective population-based
tudies of older adultmen andwomen, and examinewhether asso-
iations are independent of established cardiovascular risk factors
nd inﬂammatory markers implicated in cardiovascular risk.
. Methods
In 1998–2000, 4252 men from one General Practice in each
f 24 British towns participating in a prospective study of CVD
ere followed up at age 60–79 years (response rate 77%) [18]. In
999–2001, a parallel study of 4286 women of the same age and
n the same Practices was established, with the addition of one
own (Bristol) [19].Near identical protocols for the collectionof data
ere used in both studies. Nurses made physical measurements,
ecorded an electrocardiogram and collected fasting venous blood
amples. Serum was stored at ≤−70 ◦C for subsequent analysis.
articipants were followed up for all cause mortality and cardio-
ascular morbidity, for between 6.25 and 8.5 years with a loss of
2%. Fatal cases were ascertained through National Health Service
entral Registers using death certiﬁcates (ICD-9 codes 410–414) for
I and (ICD-9 codes 430–438) for stroke, indicating deaths with
erebrovascular disease as the underlying cause. Diagnosis of non-
atal MI or stroke was based on reports from General Practitioners
nd reviews of General Practice records, and was in accordance
ith World Health Organisation criteria [18,20]. Participants com-
leted detailed questionnaires about previous illnesses including
I or stroke, and lifestyle including cigarette smoking, alcohol con-
umption and physical activity. Own longest-held occupation (or
usband’s occupation for married, divorced and widowed women)
as coded using the Registrar General’s classiﬁcation. Town of res-
dence was recorded for women in 1998–2000 and for men at the
tart of their follow-up in 1978–80.Weight, height and seated blood
ressure were measured and fasting blood samples provided for
hemeasurement of cholesterol, triglycerides and haemostatic and
nﬂammatory markers [5,18,19,21]. All subjects provided written
nformed consent to the investigation, and the ethical approval was
rovided by relevant Local Research Ethics Committees.
We established a nested case–control study using all 390 MI
ases occurring between examination (1998–2000) and June 2006
n men and between examination (1999–2001) and September
007 in women. A total of 780 controls “frequency matched” to
ases on town of residence, gender and age in 5-year bands were
andomly selected from survivors free from incident CHD at the
nd of follow-up. Similarly a separate nested case–control study of
24 cases of stroke and 648 controls was established. Numbers of
I and stroke cases were constrained by the numbers of relevant
vents, so two controls per case were used to increase statistical
ower and precision of estimates of relative risks between TNF,
I and stroke as well as with other CVD risk factors. In the sample
ith complete data, therewere 362MI cases, fromwhichwewould
ave had 80% power to detect a relative risk of 1.59 in the top tertile
f TNF compared to the bottom tertile, at the 5% statistical signiﬁ-
ance level. From299 cases of strokewewould have had 80% power
o detect a relative risk of 1.68 in the top tertile of TNF compared to
he bottom tertile at the 5% statistical signiﬁcance level, assuming
controls per case.
TNF (pg/mL) was measured from stored frozen serum sam-
les using a commercially available high-sensitivity ELISA (R&D
ystems, Abingdon, UK) by an investigator blinded to case–controlsis 205 (2009) 302–308 303
status of the samples. The coefﬁcient of variation was 8.4% intra-
assay and 12.5% inter-assay. In 158 men from two towns, TNF
was measured in samples obtained both in 1996 and in 2000 to
enable intra-individual comparisonsover time (regressiondilution)
[22].
2.1. Statistical methods
Highly skewed variables were natural log transformed. Means
and standard deviations of baseline characteristics of cases and
controls aged 60–79 years were calculated. Continuous variables
were adjusted for gender, baseline region of residence and age at
examination. Distributions of categorical variables were examined.
Tertiles of TNFweredeﬁned in theMI control sample. Associations
between TNF tertiles and covariates were examined using one-
way ANOVA. Unmatched logistic regression analyses were used to
examine associations between TNF tertiles and MI. Models were
ﬁrst adjusted for gender, age and region. Further adjustments for
cardiovascular risk factors (selected a priori) were ﬁtted as contin-
uous variables except for; smoking (current, ex or never), alcohol
use (1–2 drinks/day or other) physical activity (more or less than
3h ofmoderate/vigorous activity perweek), and history of diabetes
(present or absent).
For MI, regression models were ﬁrst adjusted for glucose and
insulin (both natural log transformed) and then for novel risk fac-
tors which are consistently associated with CHD (log transformed
C reactive protein (CRP) and IL-6). For stroke, adjustments were
made for CRP and IL-6. Linear regression was used to model the
association between risk of MI (or stroke) and continuous TNF
both as linear and log2 transformation (to assess the effect of a
doubling of TNF level). Gender and age differences in the TNF-
CVD associations were tested using likelihood ratio (LR) tests for
interactions. All reported p-values are 2-sided. Sensitivity analyses
excluded participants with pre-existing CVD (self-report of MI or
stroke at any questionnaire between 1978–80 and 1998–2000 in
men and in 1999/2000 questionnaire in women).
The authors had full access to the data and take responsibility




For the MI case–control groups, data were available for 362 of
390 cases (267 men and 95 women, mean age 70.9 years) and for
698 of 780 controls. Cases differed from controls in having higher
prevalence of pre-existing CVD and diabetes (Table 1). Cases had
higher prevalence of smokers, fewer drinkers of 1–2 units of alco-
hol/day and fewer physically active participants (all p<0.05). They
had higher systolic blood pressure (SBP) and lower forced expira-
tory volume (FEV1) but similar bodymass index (BMI) and diastolic
blood pressure (DBP). Cases had less favourable lipid and inﬂam-
matorymarkers. Geometric mean TNF level was 11.4% (95% CI 9.5,
13.3%) higher in MI cases than controls; 1.84pg/mL (IQR 1.29, 2.42)
compared to 1.63pg/mL (IQR 1.19, 2.18) p (difference) <0.001.
TNF data were available for 299 of 324 stroke cases and 587
of 648 controls. Mean age of cases was 71.3 years, and 63% were
male. Caseshadhigherprevalenceofpre-existingCVD,diabetes and
smokers than controls (all p<0.05). They had higher blood pressure
and lower FEV1 but similar BMI. Cases had lower total cholesterol
and higher IL-6, ﬁbrinogen and white blood cell count (although
not CRP). Differences between cases and controls were less marked
than in the MI study population. TNF levels were slightly higher
among the stroke cases than controls 1.88pg/mL (IQR 1.28, 2.34)
compared to 1.75pg/mL (IQR 1.32, 2.36) p=0.079 (Table 2).
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Table 1
Baseline characteristics (age 60–79) of the MI case and control populations: mean (SD) unless otherwise speciﬁed.a.
MI cases (n=362) MI controls (n=698) Difference (p-value)
Demographic/questionnaire
Age (years) 70.91 (5.48) 70.80 (5.44) Matched
Male, n (%) 267 (73.6) 512 (73.1) Matched
Northern region of residence, n (%)b 150 (41.0) 286 (41.4) Matched
Non-manual occupation, n (%)b 152 (44.4) 319 (47.9) 0.298
Prior evidence of MI or stroke, n (%) 107 (29.6) 117 (16.8) <0.001
History of diabetes, n (%) 55 (20.6) 55 (10.7) <0.001
1–2 alcoholic drinks/day, n (%) 126 (37.8) 299 (46.4) 0.010
Current smoker, n (%) 75 (20.72) 93 (13.3) 0.004
Physical activity (inactive/occasional), n (%) 231 (66.4) 391 (58.6) 0.016
Physical measurements
Body mass index (kg/m2)c,d 27.11 (4.26) 27.02 (3.95) 0.728
Systolic blood pressure (mmHg)c,d,e 153.94 (27.22) 148.55 (24.16) 0.001
Diastolic blood pressure (mmHg)c,d,e 83.85 (12.07) 83.22 (11.52) 0.409
FEV1 (L/min)c,d, f 2.15 (0.55) 2.23 (0.60) 0.028
Lipids/metabolic markers
Total cholesterol (mMol/L)c 6.24 (1.22) 6.08 (1.07) 0.027
HDL cholesterol (mMol/L)c 1.31 (0.33) 1.41 (0.36) <0.001
Triglyceride (mMol/L)c,e ,g 1.80 (1.32, 2.40) 1.58 (1.14, 2.12) <0.001
Insulin (mU/L)c,e ,g 9.25 (5.57, 13.61) 7.85 (5.37, 11.07) <0.001
Glucose (mMol/L)c,e ,g 6.19 (5.36, 6.38) 5.84 (5.37, 6.12) <0.001
Inﬂammatory and haemostatic markers
TNF(pg/mL)c,g 1.84 (1.29, 2.42) 1.63 (1.19, 2.18) <0.001
C-Reactive Protein (mg/L)c,g 2.41(1.08, 5.58) 1.77 (0.90, 3.60) <0.001
IL-6(pg/mL)c,e ,g 2.99 (1.89, 4.26) 2.43 (1.54, 3.47) <0.001
Fibrinogen (g/L)c,e ,g 3.47 (3.03, 3.98) 3.26 (2.85, 3.75) <0.001
White cell count (1ˆ09/L)c,e ,g 7.27 (6.01, 8.84) 6.80 (5.68, 7.98) <0.001
a Case–control sample is maximum available.
b Reported in 1978–1980 (age 40–59 years) for men and in 1998–2000 (age 60–79 years) for women.




























fAdjusted for nurse number.
e Adjusted for time of day.
f Adjusted for height squared.
g Analysed as natural log transformed variable, geometric mean (IQR) reported o
.2. Baseline correlates of TNF˛
Table 3 presents associations between TNF and potential con-
ounders across thirds of the MI control population (the larger
ontrol population). Increasing TNF levels were associated with
emale gender, but not with age or behavioural factors. Increas-
ng TNFwas associated with higher BMI, triglyceride, insulin and
lucose (borderline) and lower HDL. TNFwas also positively asso-
iated with CRP, IL-6, ﬁbrinogen, white blood cell count, plasma
iscosity, coagulation factor VIII, D-dimer, von Willebrand factor
vWF) and tissue-plasminogen activator (t-PA). Not all correla-
ions between natural log TNF and covariates reached levels of
onventional statistical signiﬁcance (p<0.05), those that did reach
igniﬁcance were all of moderate magnitude r<0.25 (e.g. r=0.17,
p<0.05) for CRP and r=0.16, (p<0.05) for IL-6; r=0.20 (p<0.05) for
lasma viscosity). Similar associations were observed in the stroke
ontrol population (data not shown).
.3. Association of TNF˛ with risk of MI
Table 4 summarizes associations between MI and tertiles of
NF.Model 1was adjusted for gender, age and regionof residence;
he odds ratio (OR) for MI associated with the highest compared to
he lowest TNF tertile was 1.75 (95%CI 1.22, 2.49) and there was
signiﬁcant linear trend in ORs across the tertiles (p=0.002). After
djustment for established, behavioural and metabolic cardiovas-
ular risk factors, the OR was attenuated to 1.44 (95%CI 0.99, 2.11)
ut the linear trend remained (Table 4). Adjustment for CRPand IL-6
ttenuated the OR; 1.33 (95% CI 0.91, 1.96) and abolished the linear
rend. A doubling of TNF level was associated with increased OR
orMI: 1.34 (95%CI 1.11, 1.60), whichwas reduced on adjustment forinal scale.
established and metabolic risk factors, and completely attenuated
by adjustment for inﬂammatory markers. There was no evidence
that associations betweenMI and tertiles of TNF varied by gender
or age (LR test p=0.101, p=0.972 respectively). Likewise, interac-
tions were not observed for log2 TNF and gender or age (LR test
p=0.684, p=0.720 respectively).
Repeating analyses excluding 180 participantswith pre-existing
CVD, produced similar results, althoughpoint estimateswerewider
due to loss of power and estimates were further attenuated by
adjustments, eliminating the trend in CHD.
3.4. Association of TNF˛ with risk of stroke
No signiﬁcant associations between TNF and stroke were
observed in multivariate models (Table 5). OR for stroke associ-
ated with top compared to bottom TNF tertile was 1.12 (95%CI
0.75, 1.66). There was no evidence of an interaction between gen-
der andTNFonstroke (LR testp=0.319), or age (LR testp=1). There
was not evidence of an association between continuous TNF and
stroke; OR for doubling of TNF 1.15 (95%CI 0.95, 1.39). Excluding
133 participants with prior CVD conﬁrmed main analysis results.
3.5. Extent of regression dilution effect
Using Rosner’s method [23], a regression dilution ratio of 0.25
(95%CI 0.15, 0.35) for TNF was calculated in 158 men with TNF
levels measured 4 years apart [22].4. Discussion
In this, the largest prospective population-based study reported
to date on serum TNF levels and risk of CVD, higher serum TNF
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Table 2
Baseline characteristics (age 60–79) of the stroke case and control populations: mean (SD) unless otherwise speciﬁed.a.
Stroke cases (n=299) Stroke controls (n=587) Difference (p-value)
Demographic/questionnaire
Age (years) 71.29 (5.32) 71.35 (5.24) Matched
Male, n (%) 191 (63.4) 372 (63.9) Matched
Northern region, n (%)b 108 (36.1) 219 (37.3) Matched
Non-manual occupation, n (%)b 148 (54.8) 290 (52.9) 0.609
Prior evidence of MI or stroke, n (%) 84 (28.1) 89 (15.2) <0.001
History of diabetes, n (%) 31 (16.2) 37 (10.0) 0.030
1–2 alcoholic drinks/day, n (%) 105 (38.6) 210 (38.5) 0.937
Current smoker, n (%) 51 (17.1) 57 (9.7) 0.004
Physical activity (inactive/occasional), n (%) 196 (71.0) 377 (66.8) 0.223
Physical measurements
Body mass index (kg/m2)c,d 27.05 (4.37) 27.12 (4.11) 0.814
Systolic blood pressure (mmHg)c,d,e 154.10 (25.01) 149.13 (24.24) 0.005
Diastolic blood pressure (mmHg)c,d,e 84.84 (12.60) 82.36 (11.18) 0.003
FEV1 (L/min)c,d, f 2.09 (0.57) 2.24 (0.52) <0.001
Lipids/metabolic markers
Total cholesterol (mMol/L)c 6.12 (1.22) 6.31 (1.17) 0.024
HDL cholesterol (mMol/L)c 1.43 (0.40) 1.42 (0.36) 0.736
Triglyceride (mMol/L)c,e ,g 1.64 (1.10, 2.31) 1.69 (1.23, 2.29) 0.363
Insulin (mU/L)c,e ,g 8.53 (5.31, 12.02) 7.96 (5.03, 10.93) 0.159
Glucose (mMol/L)c,e ,g 6.05 (5.34, 6.19) 5.88 (5.32, 6.12) 0.085
Inﬂammatory and haemostatic markers
TNF (pg/mL)c,g 1.88 (1.28, 2.34) 1.75 (1.32, 2.36) 0.079
C-Reactive protein (mg/L)c,g 2.12 (1.03, 4.44) 1.92 (0.91, 4.16) 0.239
IL-6(pg/mL)c,e ,g 2.83 (1.85, 4.01) 2.56 (1.64, 3.53) 0.026
Fibrinogen (g/L)c,e ,g 3.35 (2.95, 3.84) 3.28 (2.87, 3.75) 0.142
White cell count (1ˆ09/L)c,e ,g 7.22 (6.14, 8.56) 6.90 (5.74, 8.20) <0.001
a Case control sample is maximum available.
b Reported in 1978–1980 (age 40–59 years) for men and in 1998–2000 (age 60–79 years) for women.





























[Adjusted for nurse number.
e Adjusted for time of day.
f Adjusted for height squared.
g Analysed as natural log transformed variable, geometric mean (IQR) reported o
evels were associated with elevated MI risk in older adults over
7-year period. However, the association was partly attenuated
y established and metabolic risk factors, and reduced to non-
igniﬁcance by adjustment for circulating inﬂammatory markers
ssociated with CHD: CRP [2,4] and IL-6 [5]. However, TNF was
ot associated with risk of stroke.
.1. Comparison with previous studies
TNF was positively associated with some established risk fac-
ors: BMI and inversely with HDL as reported in a cross-sectional
tudy [24], but associations were not observed with total choles-
erol or blood pressure as seen in some but not all other studies
10,24]. TNF is reported to be an adipokine and is associated
ith metabolic processes [25,26], so positive associations between
NF and BMI, glucose and insulin observed here were expected.
ssociations between TNF and other “downstream” inﬂamma-
ory markers which are emerging risk predictors (ﬁbrinogen, CRP,
hite cell count, plasma viscosity, vWF, Factor VIII, t-PA and D-
imer) were modestly positive, similar to other reports [11,24] and
nlikely to result in collinearity. Higher TNF among females was
nexpected, but may be because women in this study were post-
enopausal [24].
The magnitude of the positive association of TNF with MI
djusted for established risk factors ﬁts with other ﬁndings [11,12].
o deal with the different cut-points for TNF tertiles between
tudies, the association between continuous TNF and MI risk was
xamined. The adjusted OR for log10 TNF in our study (1.18 (95%CI
.00, 1.39) was very similar to association reported elsewhere: RR
.22 (1.04, 1.43) and their RR for stroke was also null, like our study
12]. The Finnish study (of younger adults) reportednon-linearity innal scale.
the elevated risks ofMI and totalmortality:men in the threehighest
quartiles of TNF (>0.75pg/L) had similarly raised HR for MI 2.21
(95%CI 1.18–4.14) compared to the lowest quartile [12]. However in
our study, the highest TNF tertile (>1.89pg/mL) had the most ele-
vated odds ratio and linear trendswere observed across the tertiles.
Finally, the lack of association between TNF and stroke is consis-
tent with a recent study in the elderly at risk [17]. Our study con-
ﬁrms thisﬁnding inagenerallyhealthierpopulationofolderpeople.
4.2. Strengths and weaknesses
This is the largest study of TNF, CHD and stroke; it includes
more events than previous prospective population-based studies,
has a clinically relevant follow-up, and includes both genders. The
data add to the literature because few other studies report prospec-
tive data about TNF and subsequent risk of either MI [11,12,27,28]
or stroke [11] in generally healthy populations. The study popula-
tion is representativeof gender, social backgroundandgeographical
variation across the UK. This study beneﬁts from validated data
about MI and stroke events collected from GP practices using stan-
dardized procedures and then individually veriﬁed for accuracy.
The validity of this procedure has been previously reported [29].
The study also has comprehensive data on established and novel
cardiovascular risk factors. TNF levels were measured blind to
case status, using standard laboratory protocols on well-preserved
samples. The distributions of TNF were similar to age-speciﬁc
reference ranges [24]. Patterns of association between TNF and
cardiovascular risk factors were similar to other studies. Although
a single measure of TNF per subject was available, measurement
of intra-individual variability over 4 years in a subsample of 158
men is a strength [22].
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Table 3
Association between TNF (tertiles) and cardiovascular risk factors in the MI control sample (n=698).
Low (0.03–1.3) N=233 Medium (1.31–1.88) N=234 High (1.89–13.56) N=231 Trend p-valuea
Demographic/questionnaire
Age (years) 70.30 70.70 71.40 0.090
Male, n (%) 171 (73.4) 184 (78.6) 157 (68.0) 0.034
Northern region, n (%)b 96 (41.2) 94 (40.2) 96 (41.6) 0.951
Non-manual occupation, n (%)b 113 (51.6) 106 (47.5) 100 (44.6) 0.339
Evidence of stroke, n (%) 20 (11.7) 17 (9.2) 25 (15.9) 0.165
History of diabetes, n (%) 16 (9.4) 21 (11.4) 18(11.5) 0.773
1–2 alcoholic drinks/day, n (%) 102 (48.3) 107 (48.2) 90 (42.7) 0.407
Current smoker, n (%) 33 (14.2) 23 (9.9) 37 (16.0) 0.131
Physical activity (inactive/occasional), n (%) 125 (56.3) 126 (55.5) 140 (64.2) 0.122
Physical measurements
Body mass index (kg/m2)c,d 26.38 27.42 27.24 0.001
Systolic blood pressure (mmHg)c,d,e 148.59 149.33 147.66 0.757
Diastolic blood pressure (mmHg)c,d,e 83.04 82.81 83.81 0.065
FEV1 (L/min)c,d, f 2.27 2.23 2.17 0.240
Lipids/metabolic markers
Total cholesterol (mMol/L)c 6.09 6.09 6.06 0.914
HDL cholesterol (mMol/L)c 1.50 1.43 1.32 <0.001
Triglyceride (mMol/L)c,e ,g 1.44 1.59 1.71 <0.001
Insulin (mU/L)c,e ,g 7.28 7.64 8.67 0.004
Glucose (mMol/L)c,e ,g 5.71 5.88 5.94 0.056
Inﬂammatory and haemostatic markers
C-Reactive Protein (mg/L)c,g 1.41 1.74 2.25 <0.001
IL-6(pg/mL)c,e ,g 2.20 2.33 2.80 <0.001
Fibrinogen (g/L)c,e ,g 3.16 3.26 3.37 0.012
White cell count (1ˆ09/L)c,e ,g 6.61 6.64 7.14 0.003
Plasma viscosity (mPa s)c,e 1.27 1.29 1.31 <0.001
Factor VIII (IU/dL)c 141.35 138.52 148.09 0.005
Fibrin D-dimer (ng/mL)c,g 80.74 91.18 118.99 <0.001
von Willebrand factor (IU/dL)c 139.61 142.16 157.31 <0.001
t-PA (ng/mL)c,e 9.74 10.32 11.14 <0.001
a Sample (n=698) MI controls with TNF value. Trend test adjusted for age, gender, region of residence.
b Reported in 1978–1980 (age 40–59 years) for men and in 1998–2000 (age 60–79 years) for women.





















MAdjusted for nurse number.
e Adjusted for time of day.
f Adjusted for height squared.
g Geometric mean, p-value from ANOVA with ln (variable).
.3. Interpretation of results
This study suggests that associations between TNF and MI are
odest, although the high intra-individual variability in TNF lev-
ls measured 4 years apart, suggests lower long-term biological
tability of TNF (in terms of expression) than other risk factors
22]. The low regression dilution ratio (0.25) is similar to that of
nother pro-inﬂammatory cytokine IL-6, suggesting that, like IL-6,
he association of TNFwith incident CHDmay be underestimated
n studies with single measurements [5]. The modest associations
able 4
dds ratio (95% CI) of MI in men and women with TNF values in the higher tertiles com
NF MI cases MI controls OR (95% CI) with a
ertiles Model 1
ange (pg/mL)
1.89–22.90 128 186 1.75 (1.22, 2.49)
1.31–1.88 84 203 1.03 (0.71, 1.48)
0.03–1.30 77 189 1
otal 289 578 p=0.002
ontinuous Model 1
log2 (TNF)b 289 578 1.34 (1.11, 1.60)
odel 1 = age, gender and region.
odel 2 =model 1 + smoking, alcohol, physical activity, history of diabetes, BMI, SBP, DBP,
odel 3 =model 2 + insulin + glucose.
odel 4 =model 3 + IL-6 +CRP.
a Complete case analysis sample. Tertiles based on control group. p-value for test for tre
b OR of MI per 1 log2 increase in log 2(TNF), i.e. doubling of TNF.observed between TNF and MI are unlikely to be only due to
the wide range of established biological, social or behavioural risk
factors we measured (since these were adjusted for in regression
models), or due to participants having pre-existing CVD: sensitivity
analyses excluded such participants.Associations between TNF andMIwere independent of insulin
and glucose, ﬁtting with data from a prospective study of dia-
betic women, where CHD risks were elevated independent of
hyperglycemia [27]. AssociationsbetweenTNF andMIwere atten-
uated particularly when CRP and IL-6 (separately or together) were
pared to the lower tertile of the distribution (n=867).a.
djustments
Model 2 Model 3 Model 4
1.47 (1.01, 2.14) 1.44 (0.99, 2.11) 1.33 (0.91, 1.96)
0.99 (0.67, 1.44) 0.98 (0.67, 1.44) 0.94 (0.64, 1.39)
1 1 1
p=0.038 p=0.049 p=0.125
Model 2 Model 3 Model 4
1.25 (1.03, 1.51) 1.23 (1.02, 1.49) 1.18 (0.97, 1.43)
TC, HDL.
nd over tertiles.
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Table 5
Odds ratio (95% CI) of stroke in men and women with TNF values in the higher tertiles compared to the lower tertile of the distribution (n=722).a.
TNF Stroke cases Stroke controls OR (5% CI) with adjustments
Tertiles Model 1 Model 2 Model 3
Range (pg/mL)
2.07–45.30 78 161 1.12 (0.75, 1.66) 1.15 (0.76, 1.74) 1.11 (0.73, 1.69)
1.40–2.06 80 155 1.19 (0.81, 1.75) 1.13 (0.75, 1.69) 1.11 (0.74, 1.66)
0.03–1.39 76 172 1 1 1
Total 234 488 p=0.567 p=0.516 p=0.631
OR (95% CI)
Continuous Model 1 Model 2 Model 3
1 log2 (TNF)b 234 488 1.15 (0.95, 1.39) 1.14 (0.93, 1.40) 1.13 (0.92, 1.38)
Model 1 = age, gender and region.















































[odel 3 =model 2 + IL-6 +CRP.
a Complete case analysis sample. Tertiles based on control group. p-value for test
b OR of MI per 1 log2 increase in log 2(TNF), i.e. doubling of TNF.
ncluded in multivariate analyses, whilst CRP and IL-6 remained
ndependently associated with MI, suggesting that each could be
mportant pathways from TNF to MI risk. Most studies of TNF
nd MI have not adjusted for other inﬂammatory markers. One
tudy reported that adjustment for CRP, partially attenuated the
ssociation between TNF and CHD but abolished the association
ith total mortality, however that study did not include IL-6 [11].
djusting for any inﬂammatorymarkersmaybeover-adjustment in
erms of aetiology, since TNF is thought to act synergistically with
L-6 and IL-1, upstream of the acute phase response [30]. However
n our study, no statistical interaction between TNF and IL-6 onMI
r stroke was observed. Hence in biological terms, the association
f “downstream” acute-phase reactants (such as CRP, ﬁbrinogen or
hite cell count) with CVD endpoints could be primarily due to
ncreased levels of circulating TNF, IL-6 and potentially other pro-
nﬂammatory cytokines [5,7,8]. The attenuation of associations of
NF with outcome conﬁrms ﬁndings in a recurrent stroke study,
hat a proﬁle of raised inﬂammatory markers (rather than any spe-
iﬁc independent inﬂammatorymarker) is associatedwith vascular
isk [16]. Hence TNF does not add much to other inﬂammatory
arkers in predicting CHD risk. For example, CRP which probably
asmore robust associationswith CHD risk,maynotmuch improve
isk prediction [4]. Overall, due to relatively modest associations
ith CHD risk, a relatively high degree of regression dilution, and
onfounding by generalized inﬂammation, TNF is unlikely to be a
linically useful risk biomarker, although this does not diminish a
otential role in CHD aetiology.
.4. Conclusions
Our study provides further evidence that TNF is associated
ith a modestly elevated risk of MI, after adjustment for estab-
ished cardiovascular risk factors, although this association is not
ndependent from inﬂammatory markers CRP or IL-6. Associations
ith stroke were not observed. The modest association with MI
ay give insights into the process of MI risk, but TNF is unlikely
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